Your Search for 'Recordati: Pipeline, Products, Performance and Potential' returned 6 results - Page 1 of 1

• Orphan Drug Markets in Europe: Key Developments and the Strategies of Major Pharmaceutical Companies

  EURO€ 2,242.00USD$ 2,534.00GBP£ 1,495.00AUD$ 3,504.00JPY¥ 303,862.00SEK 19 933,00CHF 3'337.00CAD$ 3,250.00 Spectra Intelligence, Nov 2011 , Pages: 66
  Selected commercially successful small molecule orphan products in the US Table 6.4 Genzyme's orphan drug portfolio and 2010 sales Table 6.5 Genzyme's orphan drug pipeline Table 6.6 Actelion's orphan drug ...

• ESTEVE - Strategic SWOT Analysis Review

  EURO€ 96.00USD$ 125.00GBP£ 81.00AUD$ 122.00JPY¥ 12,342.00SEK 821,00CHF 118.00CAD$ 127.00 GlobalData, Sep 2011 , Pages: 24
  . - Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance. List of Tables List of Figures ...

• E7: The Outlook for Pharmaceuticals to 2012

  EURO€ 4,481.00USD$ 5,830.00GBP£ 3,770.00AUD$ 5,702.00JPY¥ 575,579.00SEK 38 277,00CHF 5'495.00CAD$ 5,940.00 Espicom Business Intelligence Ltd, Feb 2012
  interest. Amgen, for example, acquired the local producer Bergamo in April 2011, and reacquired a number of products previously licensed to Mantercorp, which was acquired by Hypermarcas in January 2011 ...

• Sigma-Tau S.p.A. - Strategic SWOT Analysis Review

  EURO€ 96.00USD$ 125.00GBP£ 81.00AUD$ 122.00JPY¥ 12,342.00SEK 821,00CHF 118.00CAD$ 127.00 GlobalData, Feb 2012 , Pages: 25
  . - Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance. Key Words Sigma-Tau S.p.A., SWOT analysis, SWOT ...

• US Cancer Pain Report

  EURO€ 7,648.00USD$ 9,950.00GBP£ 6,435.00AUD$ 9,732.00JPY¥ 982,393.00SEK 65 330,00CHF 9'378.00CAD$ 10,139.00 WWMR, Feb 2009 , Pages: 101
  drugs and tapentadol have the greatest potential for success among the novel agents that may enter the market soon. Cannabinoids represent a novel mechanism of action to add to the limited spectrum that ...

• Dyslipidemia: Opportunities in Cardiovascular Risk Reduction

  EURO€ 737.00USD$ 959.00GBP£ 620.00AUD$ 938.00JPY¥ 94,658.00SEK 6 295,00CHF 904.00CAD$ 977.00 Biophoenix Limited, Jul 2008 , Pages: 210
  trials, biomarkers, surrogates of atherosclerosis for drug development, and over 150 products in commercial development. It also derives market forecasts (2008-2012) and assesses market potential. Why buy ...